As per the report published by Kings Research, the global Bladder Cancer Market was valued at USD 5.39 billion in 2022 and is projected to reach USD 7.97 billion by 2030, growing at a CAGR of 5.12% from 2023 to 2030.

The bladder cancer market is expected to experience significant growth due to the increasing incidence of the disease and the availability of personalized medicine. Significant advances have been made in the diagnosis and treatment of bladder cancer, including the development of newer imaging techniques, targeted therapies, and immunotherapies. Increasing healthcare expenditure and government funding for cancer research and treatment programs are likely to contribute to the growth of the bladder cancer market. These facilitate the development of new treatments and improve patient access to existing treatments. Personalization of treatments and improvements in early detection methods also offer growth potential in the market. These advancements are expected to drive market growth in the coming years. In addition, competition in the market is intensifying, as more and more pharmaceutical companies are investing in the development of new treatments for bladder cancer. The bladder cancer market is expected to continue to grow in the coming years due to increasing awareness, research advancements, and increasing demand for effective and personalized treatments.

Key Insights

• Based on type, the treatment segment is growing at a CAGR of 4.47% over the forecast period
• Based on cancer type, the transitional bladder cancer segment is expected to dominate with a market share of 53.02% by the end of 2030
• On the basis of region, North America accounted highest market value of USD 2.03 billion in 2022

Nanostics Inc. Initiated the Clinical Trial of Bladder Cancer Diagnostic Test for Early Detection

July 2022: Nanostics Inc. commenced the clinical trial to validate a new and minimally invasive bladder cancer diagnostic test, the ClarityDX Bladder, using the ClarityDX diagnostic platform. Nanostics' ClarityDX Bladder Test uses extracellular bladder detection technology and machine learning pattern analysis to identify the most effective disease predictors for early detection of bladder cancer.

Ongoing Research Towards Targeted Therapies Augments the Market Growth

Bladder cancer research has seen recent innovations and advances. In addition, efforts are being made to develop more predictive biomarkers and improve methods for early detection of bladder cancer. Some researchers are investigating the use of advanced imaging techniques such as positron emission tomography (PET) scanning and magnetic resonance imaging (MRI) to improve the diagnosis and staging of bladder cancer. Other innovative approaches include the use of gene editing techniques and targeted therapies. This development promises to improve the prognosis and quality of life of patients with bladder cancer.

Targeted therapy is an area of active research and development in the treatment of bladder cancer. Some of the targeted drugs currently approved for bladder cancer are erdafitinib (Balversa), which targets certain genetic mutations in bladder cancer cells, and atezolizumab (Tecentriq), which targets the PD-L1 protein and stimulates the immune system to attack the cancer cells. In addition to this, other targeted therapies under investigation include FGFR inhibitors and PI3K/AKT/mTOR inhibitors, which target cell signaling pathways involved in bladder cancer growth. These targeted therapies have shown promise in clinical trials and may provide effective and personalized treatment for bladder cancer patients in the future.

Ongoing Improvements in Bladder Cancer Diagnosis and Treatment Options Drives the Market Growth

The growing incidences of bladder cancer have accelerated the need to focus on reducing the incidence of bladder cancer through anti-smoking and environmental legislation driving the need for bladder cancer treatment. The improvements in early diagnosis and treatment hold the potential for bettering patient outcomes and lessening the burden of this disease. With significant advances in the diagnosis and treatment of bladder cancer, current treatment options have increased effectiveness in some patients. Immunotherapy has emerged as an effective and promising new treatment option for bladder cancer. Drugs such as pembrolizumab and atezolizumab have been shown to improve survival in certain patients with advanced or metastatic bladder cancer, which accelerates the need to treat bladder cancer.

Asia Pacific is the Fastest Growing Region with a Forecasted CAGR of 5.86% 

The factors influencing the APAC bladder cancer market include smoking, exposure to environmental toxins, and urinary tract infections. In the Asia-Pacific region, the incidence of bladder cancer has increased over the past decade, particularly in countries such as Japan, Korea, Taiwan, and China. In some countries, particularly in Southeast Asia, tobacco use is widespread despite extensive health education campaigns about its dangers. Bladder cancer diagnosis and treatments in the Asia-Pacific region have improved significantly in recent years. The most commonly used treatments for bladder cancer are surgery, radiation therapy, and chemotherapy. The choice of treatment depends on the stage and severity of the cancer and the general health of the patient.  Research studies focus on elucidating the etiology of bladder cancer and developing targeted therapies for specific patient subgroups. Regulators are streamlining the regulatory approval process for new treatments and developing policies that encourage investment in bladder cancer research. 

Europe is the Second Largest Region With a Market Value of USD 1.74 Billion in 2022

The regional market growth is proliferated by the increased number of parasitic infections, which has accelerated the need for effective treatment of bladder cancer. The growing number of research studies with increased collaboration between researchers, healthcare providers, and regulatory authorities to address these issues and achieve better outcomes for patients with bladder cancer in the region. Healthcare providers are striving to increase patient awareness, implement more cost-effective treatment plans, and improve access to care. The increasing number of product approvals across the region for new treatments with increased investment in bladder cancer research propels the need to treat bladder cancer.

Key Players are Focusing on Product Approvals to Expand their Product Portfolio

The global bladder cancer market growth is accelerated with the presence of key vendors such as Astellas Pharma Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer, Inc, and others. Prominent players are focusing on several key business strategies, such as partnerships, mergers and acquisitions, product innovations, and joint ventures, to expand their product portfolio and increase their respective market shares across different regions.